Follow Us TR

News Details

TG Therapeutics Announces Publication of Ublituximab Phase 2 Clinical Trial Results in Multiple Sclerosis Journal

About TG Therapeutics, Inc.
  • NASDAQ: $TGTX
  • Notified: $11.75
  • 07:30 EDT

Price Chart